Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.

Schaid DJ, Spraggs CF, McDonnell SK, Parham LR, Cox CJ, Ejlertsen B, Finkelstein DM, Rappold E, Curran J, Cardon LR, Goss PE.

J Clin Oncol. 2014 Aug 1;32(22):2296-303. doi: 10.1200/JCO.2013.52.9867. Epub 2014 Mar 31.

2.

Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.

Spraggs CF, Parham LR, Hunt CM, Dollery CT.

Clin Pharmacol Ther. 2012 Apr;91(4):647-52. doi: 10.1038/clpt.2011.277. Epub 2012 Feb 22.

PMID:
22357454
3.

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.

Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, Whittaker JC, Mooser VE, Preston AJ, Stein SH, Cardon LR.

J Clin Oncol. 2011 Feb 20;29(6):667-73. doi: 10.1200/JCO.2010.31.3197. Epub 2011 Jan 18.

4.

Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.

Parham LR, Briley LP, King KS, Byrne J, Rappold E, Goss PE, Spraggs CF.

Pharmacogenomics. 2015;16(11):1227-9. doi: 10.2217/pgs.15.69. Epub 2015 Aug 12.

PMID:
26265235
5.

Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury.

Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, Day CP, Aithal GP.

J Hepatol. 2010 Dec;53(6):1049-53. doi: 10.1016/j.jhep.2010.05.033. Epub 2010 Aug 1.

PMID:
20800921
6.

Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.

Boyle FM, Smith IE, O'Shaughnessy J, Ejlertsen B, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Amonkar M, Huang Y, Rappold E, Williams LS, Wang-Silvanto J, Kaneko T, Finkelstein DM, Goss PE; TEACH Investigators.

Eur J Cancer. 2015 Apr;51(6):685-96. doi: 10.1016/j.ejca.2015.02.005. Epub 2015 Mar 6.

PMID:
25752740
7.

The association between the genetic polymorphism of HLA-DQA1, DQB1, and DRB1 and serum alanine aminotransferase levels in chronic hepatitis C in the Chinese population.

Yu RB, Hong X, Ding WL, Tan YF, Zhang YX, Sun NX, Wu GL, Zhan SW, Ge DF.

J Gastroenterol Hepatol. 2008 Sep;23(9):1394-402. Epub 2007 Nov 19.

PMID:
18028350
8.

HLA-DRB1,-DQA1 and -DQB1 allele and haplotype frequencies in female patients with early onset breast cancer.

Mahmoodi M, Nahvi H, Mahmoudi M, Kasaian A, Mohagheghi MA, Divsalar K, Nahavandian B, Jafari A, Ansarpour B, Moradi B, Aghamohammadi A, Amirzargar A.

Pathol Oncol Res. 2012 Jan;18(1):49-55. doi: 10.1007/s12253-011-9415-6. Epub 2011 Jul 1.

PMID:
21720852
9.

Lapatinib-induced hepatitis: a case report.

Peroukides S, Makatsoris T, Koutras A, Tsamandas A, Onyenadum A, Labropoulou-Karatza C, Kalofonos H.

World J Gastroenterol. 2011 May 14;17(18):2349-52. doi: 10.3748/wjg.v17.i18.2349.

10.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.

J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.

11.

Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, Leung WL, Russo MW, Newstat B, Wang L, Chen G, Oliva C, Gomez H.

J Clin Oncol. 2013 Jun 1;31(16):1947-53. doi: 10.1200/JCO.2011.40.5241. Epub 2013 Mar 18.

12.

HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity.

Stephens C, López-Nevot MÁ, Ruiz-Cabello F, Ulzurrun E, Soriano G, Romero-Gómez M, Moreno-Casares A, Lucena MI, Andrade RJ.

PLoS One. 2013 Jul 9;8(7):e68111. doi: 10.1371/journal.pone.0068111. Print 2013. Erratum in: PLoS One. 2014;9(10):e112165.

13.

The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01.

Hirasawa M, Hagihara K, Okudaira N, Izumi T.

PLoS One. 2015 Jun 22;10(6):e0130928. doi: 10.1371/journal.pone.0130928. eCollection 2015.

14.

The DQB1 *03:02 HLA haplotype is associated with increased risk of chronic pain after inguinal hernia surgery and lumbar disc herniation.

Dominguez CA, Kalliomäki M, Gunnarsson U, Moen A, Sandblom G, Kockum I, Lavant E, Olsson T, Nyberg F, Rygh LJ, Røe C, Gjerstad J, Gordh T, Piehl F.

Pain. 2013 Mar;154(3):427-33. doi: 10.1016/j.pain.2012.12.003. Epub 2012 Dec 13.

PMID:
23318129
15.

HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.

Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS, Fraser DJ, Stinnett S, Briley LP, Mitrica I, Spraggs CF, Nelson MR, Tada H, du Bois A, Powles T, Kaplowitz N, Pandite LN.

Clin Cancer Res. 2016 Mar 15;22(6):1371-7. doi: 10.1158/1078-0432.CCR-15-2044. Epub 2015 Nov 6.

PMID:
26546620
16.

HLA class-II allele frequencies in Turkish breast cancer patients.

Gun FD, Ozturk OG, Polat A, Polat G.

Med Oncol. 2012 Jun;29(2):466-71. doi: 10.1007/s12032-011-9873-4. Epub 2011 Mar 4.

PMID:
21373933
17.

A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region.

Urabe Y, Ochi H, Kato N, Kumar V, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Lo PH, Tanikawa C, Omata M, Koike K, Miki D, Abe H, Kamatani N, Toyota J, Kumada H, Kubo M, Chayama K, Nakamura Y, Matsuda K.

J Hepatol. 2013 May;58(5):875-82. doi: 10.1016/j.jhep.2012.12.024. Epub 2013 Jan 12.

PMID:
23321320
18.

HLA-C alleles confer risk for anti-citrullinated peptide antibody-positive rheumatoid arthritis independent of HLA-DRB1 alleles.

Nordang GB, Flåm ST, Maehlen MT, Kvien TK, Viken MK, Lie BA.

Rheumatology (Oxford). 2013 Nov;52(11):1973-82. doi: 10.1093/rheumatology/ket252. Epub 2013 Jul 30.

19.

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.

Decensi A, Puntoni M, Pruneri G, Guerrieri-Gonzaga A, Lazzeroni M, Serrano D, Macis D, Johansson H, Pala O, Luini A, Veronesi P, Galimberti V, Dotti MC, Viale G, Bonanni B.

Cancer Prev Res (Phila). 2011 Aug;4(8):1181-9. doi: 10.1158/1940-6207.CAPR-10-0337. Epub 2011 Jun 17.

20.

Anti-tuberculosis drug-induced liver injury in Shanghai: validation of Hy's Law.

Shen X, Yuan Z, Mei J, Zhang Z, Guo J, Wu Z, Wu J, Zhang H, Pan J, Huang W, Gong H, Yuan D, Xiao P, Wang Y, Shuai Y, Lin S, Pan Q, Zhou T, Watkins PB, Wu F.

Drug Saf. 2014 Jan;37(1):43-51. doi: 10.1007/s40264-013-0119-6.

PMID:
24203912
Items per page

Supplemental Content

Write to the Help Desk